Advertisement

Acta Neuropathologica

, Volume 78, Issue 1, pp 22–27 | Cite as

Comparison of four staining methods on the detection of neuritic plaques

  • H. M. Wisniewski
  • G. Y. Wen
  • K. S. Kim
Regular Papers

Summary

The sensitivities of four staining methods for detecting the presence of neuritic plaques in the normal aging. Alzheimer disease (AD) and Down's syndrome (DS) brains were compared. The Bielschowsky method and immunostaining with monoclonal antibody (4G8, IgG2b) to β-amyloid revealed the highest numbers of plaques. The thioflavin S-staining method showed about 38%–70% of plaques as shown by the Bielschowsky method. The Bodian method is the least sensitive method revealing about 26%–39% of plaques as compared with the Bielschowsky method. In the first part of this study, serial sections (6 μm) of the plaques from AD and DS brains were cut and stained with Bielschowsky, thioflavin S and Bodian methods, respectively. In the second part, Bielschowsky and immunostaining methods were used to stain serial sections (6 μm) of plaques from the same block of brain tissue. A Zeiss Axiophot fluorescence microscope, coupled with the Cambridge Quantiment 970 and Zeiss Videoplan computerized image analyzers, was used to quantify the number of plaques. Both Bielschowsky and immunostaining methods revealed the presence of both the peripheral zone (halo) and the central core of a classical plaque and resulted in the highest plaque counts. The central core of the thioflavin S-stained plaques were still clearly present, but the peripheral zone was barely visible. In Bodian stain, however, both central core and peripheral zone were poorly stained and not detectable by computer. They were quantified by human eye observation. The Bielschowsky method and immunostaining with pretreatment with formic acid are, therefore, the most sensitive methods showing the highest contrast of plaque image and thus facilitate the quantification of plaque by computer. However, Bielschowsky method is not a specific method for plaques. It stains neurofibrillary tangles and blood vessels regardless of whether they have amyloid deposits or not. Immunostaining is a sensitive and specific method for amyloid and exhibits low background staining. It confirmed that all Bielschowsky-stained plaques contained amyloid deposit.

Key words

Neuritic plaques Alzheimer disease Down syndrome Normal aging Immunostaining 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bielschowsky M (1904) Die Silberimpregnation der Neurofibrillen. J Psycholo-Neurol 3:169–188Google Scholar
  2. 2.
    Delaere P, Duyckaerts C, Brion JP, Poulain V, Hauw J-J (1989) Tau, PHF and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and SDAT. Acta Neuropathol (in press)Google Scholar
  3. 3.
    Duyckaerts C, Brion JP, Hauw JJ, Flament-Durand J (1987) Quantitative assessment of the density of neurofibrillary tangles and senile plaques in senile dementia of the Alzheimer type. Comparison of immunocytochemistry with a specific antibody and Bodian's protargol method. Acta Neuropathol (Berl) 73:167–170Google Scholar
  4. 4.
    Giallyas F (1971) Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung 19:1–8Google Scholar
  5. 5.
    Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42:1097–1104Google Scholar
  6. 6.
    Kim KS, Miller DL, Sapienza VJ, Chen CM, Bai C, Grundke-Iqbal I, Currie JR, Wisniewski HM (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2:121–130Google Scholar
  7. 7.
    Kitamoto T, Ogomori K, Tateishei J, Prusiner SB (1987) Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 57:230–236Google Scholar
  8. 8.
    Kurucz J, Charbonneau R, Kurucz A, Ramsey P (1981) Quantitative clinico-pathologic study of senile dementia. J Am Geriatr Soc 29:158–163Google Scholar
  9. 9.
    Luna LG (1960) Manual of histologic staining methods of the Armed Forces Institute of Pathology, 3rd edn. McGraw-Hill, New York Toronto London SydneyGoogle Scholar
  10. 10.
    Munoz-Garcia D, Pendlebury WW, Kessler JB, Perl DP (1986) An immunocytochemical comparison of cytoskeletal proteins in aluminium-induced and Alzheimer-type neurofibrillary tangles. Acta Neuropathol (Berl) 70:243–248Google Scholar
  11. 11.
    Rudelli RD, Ambler MW, Wisniewski HM (1984) Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol (Berl) 64:273–281Google Scholar
  12. 12.
    Schwartz P (1970) Amyloidosis: cause and manifestation of senile deterioration. CC Thomas, Springfield, Ill, pp 5–71Google Scholar
  13. 13.
    Terry RD, Peck A, DeTeresa R, Schechter R, Horoupain DS (1981) Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 10:184–192Google Scholar
  14. 14.
    Wen GY, Shek JW, Wisniewski HM (1987) Staining difference of neuritic plaques by Bielschowsky, thioflavin S and Bodian methods. J Neuropathol Exp Neurol [Abstr] 46:338Google Scholar
  15. 15.
    Wisniewski HM, Merz GS (1985) Neuropathology of the aging brain and dementia of the Alzheimer type. In: Gaitz CM, Samorajski T (ed) Aging 2000; our health care destiny, vol 1, Biochemical issues. Springer, New York, pp 231–243Google Scholar
  16. 16.
    Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Ihara Y (1988) A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by B protein immunostaining. Acta Neuropathol 76:541–549Google Scholar
  17. 17.
    Yamamoto T, Hirano A (1986) A comparative study by modified Bielschowsky, Bodian and thioflavin S Stains on Alzheimer's neurofibrillary tangles. Neuropathol Apl Neurobiol 12:3–9Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • H. M. Wisniewski
    • 1
  • G. Y. Wen
    • 1
  • K. S. Kim
    • 1
  1. 1.New York State Institute for Basic Research in Developmental DisabilitiesStaten IslandUSA

Personalised recommendations